top of page
The Professional Network for Healthcare Experts
Celltrion licenses Kaigene anti-APRIL antibody KG013 for up to $580.5 million
Celltrion has licensed Kaigene's next-generation anti-APRIL antibody KG013 in a global agreement worth up to $580.5 million plus royalties.
nuaxia
2 hours ago2 min read
CSL and Alentis sign lixudebart partnership worth up to $1.555bn plus profit share
CSL and Alentis Therapeutics have entered a global lixudebart partnership worth up to $1.555 billion, with future profits shared between the companies.
nuaxia
Oct 62 min read
bottom of page